VANDA PHARMACEUTICALS INC. Unrecognized Tax Benefits that Would Impact Effective Tax Rate
VANDA PHARMACEUTICALS INC. (VNDA) had Unrecognized Tax Benefits that Would Impact Effective Tax Rate of $19.60 million as of 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate · last filed 2026-02-12
- 2025-12-31: Unrecognized Tax Benefits that Would Impact Effective Tax Rate $19.60M.
- 2024-12-31: Unrecognized Tax Benefits that Would Impact Effective Tax Rate $18.80M.
- 2023-12-31: Unrecognized Tax Benefits that Would Impact Effective Tax Rate $18.30M.
- 2022-12-31: Unrecognized Tax Benefits that Would Impact Effective Tax Rate $15.50M.
| Period end | Unrecognized Tax Benefits that Would Impact Effective Tax Rate |
|---|---|
| 2025-12-31 | $19.60M 10-K · filed 2026-02-12 |
| 2024-12-31 | $18.80M 10-K · filed 2025-02-14 |
| 2023-12-31 | $18.30M 10-K · filed 2024-02-08 |
| 2022-12-31 | $15.50M 10-K · filed 2023-02-09 |
| 2021-12-31 | $12.90M 10-K · filed 2022-02-24 |
| 2020-12-31 | $11.20M 10-K · filed 2021-02-11 |
| 2019-12-31 | $9.70M 10-K · filed 2020-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |